NERV — Minerva Neurosciences Balance Sheet
0.000.00%
- $260.51m
- $238.21m
Annual balance sheet for Minerva Neurosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 60.8 | 36.1 | 40.9 | 21.4 | 82.3 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 62.2 | 40.2 | 42 | 22.3 | 83.1 |
| Net Property, Plant And Equipment | 0 | 0.016 | 0.011 | 0.005 | 0 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 77.1 | 55.1 | 56.9 | 37.1 | 98 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 2.82 | 1.38 | 3.34 | 2.84 | 2.29 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 69.1 | 75.1 | 85.4 | 62.8 | 234 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 7.98 | -20 | -28.5 | -25.7 | -136 |
| Total Liabilities & Shareholders' Equity | 77.1 | 55.1 | 56.9 | 37.1 | 98 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |